NeuroDerm

NeuroDerm1 post
11 May, 2015
0

FDA clears Neuroderm clinical trials

Makes Statement

The FDA clears Israeli pharmaceutical firm NeuroDerm’s U.S. clinical studies to proceed in the second half of this year.

Having lifted the clinical hold in the first half of 2015 means that our U.S. clinical development program of ND0612H and ND0612L is proceeding on track. Parkinson’s patients have been hoping for a less invasive, non-surgical alternative that can deliver levodopa continuously. We remain committed to the execution of our plan to bring these product candidates to the market as soon as possible, and to make a significant impact on the lives of Parkinson’s patients.

Do you love news? Help us add and summarize the world's news. Find out more